Brilaroxazine
- Generic Name
- Brilaroxazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25Cl2N3O3
- CAS Number
- 1239729-06-6
- Unique Ingredient Identifier
- X8L60BA01I
- Background
Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.
- Indication
Investigated for the treatment of schizophrenia and schizoaffective disorder.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Reviva Pharmaceuticals
- Target Recruit Count
- 690
- Registration Number
- NCT05184335
- Locations
- 🇺🇸
Reviva site, Richardson, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.